Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Trial Profile

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms CLEAR
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2022 Results of a pooled analysis from two clinical trials: CLEAR and CLARITY trials assessing level of response in lower limbs versus other body regions in patient with moderate to severe psoriasis published in the BioDrugs
    • 25 Apr 2021 Results of a pooled analysis from two clinical studies: CLEAR and CLARITY presented at the American Academy of Dermatology Virtual Meeting Experience 2021
    • 25 Apr 2021 Results (n=1778) of updated analysis from CLEAR and CLARITY Trials; assessing the incremental burden of comorbid psoriatic arthritis on the clinical efficacy and safety of secukinumab vs ustekinumab among patients with moderate to severe plaque psoriasis, presented at the American Academy of Dermatology Virtual Meeting Experience 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top